GDF15 and cancer: AV-380 and Ponsegromab, also anti-GDF-15 antibodies, are under evaluation as potential therapies for cancer-induced cachexia in non-small cell lung, pancreatic, and colorectal cancer patients, as well as in metastatic colorectal cancer, through Phase I and II studies.